FDA 483 - Eli Lilly & Company - September 15, 2023
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Eli Lilly & Company in Indianapolis, IN, received a Form 483 with five observations following an FDA inspection from September 11-15, 2023. The firm failed to adhere to its approved Risk Evaluation and Mitigation Strategy (REMS) for Zyprexa Relprevv, specifically regarding the certification of healthcare providers, pharmacies, and healthcare settings. Additionally, the company did not ensure proper documentation of patient safe-use conditions or timely patient enrollment in the REMS registry, indicating significant non-compliance with drug safety protocols.
ID · 49ac02bf-312b-43ae-96e2-4cf015602e85